Terms: = Thyroid cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Clinical Outcome
5 results:
1. TMPRSS4 is a novel biomarker and correlated with immune infiltration in thyroid carcinoma.
Xu X; Sun T; Jing J
BMC Endocr Disord; 2022 Nov; 22(1):280. PubMed ID: 36380313
[TBL] [Abstract] [Full Text] [Related]
2. Association of immune checkpoint inhibitors with respiratory infections: A review.
Hamashima R; Uchino J; Morimoto Y; Iwasaku M; Kaneko Y; Yamada T; Takayama K
Cancer Treat Rev; 2020 Nov; 90():102109. PubMed ID: 33038863
[TBL] [Abstract] [Full Text] [Related]
3. The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon.
Grimm WA; Messer JS; Murphy SF; Nero T; Lodolce JP; Weber CR; Logsdon MF; Bartulis S; Sylvester BE; Springer A; Dougherty U; Niewold TB; Kupfer SS; Ellis N; Huo D; Bissonnette M; Boone DL
Gut; 2016 Mar; 65(3):456-64. PubMed ID: 25645662
[TBL] [Abstract] [Full Text] [Related]
4. thyroid cancers express CD-40 and CD-40 ligand: cancers that express CD-40 ligand may have a greater risk of recurrence in young patients.
Costello A; Rey-Hipolito C; Patel A; Oakley K; Vasco V; Calabria C; Tuttle RM; Francis GL
Thyroid; 2005 Feb; 15(2):105-13. PubMed ID: 15753667
[TBL] [Abstract] [Full Text] [Related]
5. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome.
von Wasielewski R; Rhein A; Werner M; Scheumann GF; Dralle H; Pötter E; Brabant G; Georgii A
Cancer Res; 1997 Jun; 57(12):2501-7. PubMed ID: 9192832
[TBL] [Abstract] [Full Text] [Related]
